Development of a novel therapy using the iron chelator for advanced hepatocellular carcinoma

点击翻译按钮获取中文摘要

We investigated the anti-tumor effect and the fibrosing suppression effect of the iron chelator deferoxamine (DFO) in vitro and in the model rats using diethylnitrosamine and choline-deficient L-amino acid-defined diet. We proved the antiproliferative effect of DFO in hepatoma cell line. In the vivo model, the body weight and liver weight in the DFO therapy group was significantly lower than those in the control group, and the tumor growth was significantly suppressed in the DFO therapy group comparing the control group. The iron chelator has few DNA damage and has the potential of hepatma specific action different from the traditional anticancer drugs. In this study, we founded that the iron chelator has the potential of a novel antiproliferative drug in patients who had advanced hepatocellular carcinoma and were non-responders for anticancer drugs.